한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제27권4호
  • /
  • Pages.199-206
  • /
  • 2017
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

폐경기 증상을 완화시키기 위한 개별화 호르몬 요법에 대한 고찰: 다른 위험요소가 없는 폐경기 여성을 중심으로

Hormone Therapy Review for Perimenopausal Symptoms: Focused on Perimenopausal Women without Other Risk Factors

  • Lee, Young Mee (College of Pharmacy, Chungnam National University) ;
  • Yun, Hwi-yeol (College of Pharmacy, Chungnam National University)
  • 투고 : 2017.10.11
  • 심사 : 2017.11.22
  • 발행 : 2017.12.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

As the population ages, the life of women after menopause becomes much longer than the past, and the quality of life of old age becomes increasingly principal issue. There is a period that women experience the physical symptoms of menopause, although there are differences in degree, and the management of this period is a suitable time for women to improve their quality of life. According to the menopausal hormone therapy (MHT) and Timing Hypothesis, which has been proven in the Kronos Early Estrogen Prevention Study (KEEPS) and the Early vs Late Intervention Trial with Estradiol (ELITE) study, a relatively young woman before and after menopause can benefit from long-term beneficial effects such as prevention of osteoporosis and cardiovascular disease by early initiation of hormone therapy to alleviate menopausal symptoms. MHT should be considered for all women in healthy (without other important diseases) menopausal years, expecting to improve their quality of life through symptom relief in menopausal women and, in the long term, to prevent cardiovascular disease and osteoporosis. When applying hormone therapy to individuals, it is necessary to establish various treatment strategies according to the menopausal symptoms of individual patients (individualization of treatment) and judge the suitability of clinical application.

키워드

참고문헌

  1. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(suppl 1):3-63.
  2. Yoon BK. Development of the protocol to evaluate the effects of hormone therapy in postmenopausal women. The 3rd Symposium on Women's Health Research. 2014.9.26
  3. Available from http://opendata.hira.or.kr/op/opc/olap3thDsInfo.do
  4. Cho MK, Park HM. The National Use of Hormonal Therapy in Postmenopausal Women in 2010. J Korean Soc Menopause 2011; 17:150-4. https://doi.org/10.6118/jksm.2011.17.3.150
  5. Han KO. Postmenopausal Hormone Therapy Up-to-date. The Korean Journal of Endocrinology 2007;22(5).
  6. Park HM. Female hormone therapy tendency after WHI. The Korean Clinical Elderly Medical Society. In: Fall Conference 2006.
  7. Miller VM, Jenkins GD, Biernacka JM, et al. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiol Genomics 2016;48(1):33-41. https://doi.org/10.1152/physiolgenomics.00029.2015
  8. Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med 2016;374(13):1221-31. https://doi.org/10.1056/NEJMoa1505241
  9. Gallagher JC, Palacios S, Ryan KA, et al. Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. Menopause 2016;23(10):1083-91. https://doi.org/10.1097/GME.0000000000000694
  10. Cintron D, Lahr BD, Bailey KR, et al. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause 2017 Aug 21.
  11. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8(1):3-12. https://doi.org/10.1080/13697130500042417
  12. Kling JM, Lahr BA, Bailey KR, et al. Endothelial function in women of the Kronos Early Estrogen Prevention Study. Climacteric 2015;18(2):187-97. https://doi.org/10.3109/13697137.2014.986719
  13. Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause 2017;24(3):238-46. https://doi.org/10.1097/GME.0000000000000756
  14. Gleason CE, Dowling NM, Wharton W, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Med 2015;12(6):e1001833. https://doi.org/10.1371/journal.pmed.1001833
  15. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310(13):1353-68. https://doi.org/10.1001/jama.2013.278040
  16. Lindsay R, Gallagher JC, Kleerekoper M, et al. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16(4):372-9. https://doi.org/10.1007/s00198-004-1773-4
  17. Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;20:59(1):2-6. https://doi.org/10.1016/j.maturitas.2007.10.007
  18. Sturdee DW, Archer DF, Rakov V, et al. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric 2008;11(1):63-73. https://doi.org/10.1080/13697130701852390
  19. De Franciscis P, Cobellis L, Fornaro F, et al. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet 2007;98(2):138-42. https://doi.org/10.1016/j.ijgo.2007.04.008
  20. Sturdee DW, Pines A; International Menopause Society Writing Group, Archer DF, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14: 302-20. https://doi.org/10.3109/13697137.2011.570590
  21. Bodmer C, Steimann S, Schiessl K, et al. Hormonersatztherapie (HET) - Guidelines fur die Schweiz. Gynakol Endokrinol 2009;3:26-30
  22. Coelingh Bennink HJ. Are all estrogens the same? Maturitas 2004;47(4):269-75. https://doi.org/10.1016/j.maturitas.2003.11.009
  23. Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause 2002;9(4):253-63. https://doi.org/10.1097/00042192-200207000-00006
  24. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treatment 2008;107:103-11.
  25. Olie V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-93. https://doi.org/10.1097/gme.0b013e3181f9f7c3
  26. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
  27. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409. https://doi.org/10.1136/bmj.e6409
  28. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. Women's Health 2006;15:35-44. https://doi.org/10.1089/jwh.2006.15.35
  29. Stute P, Becker HG, Bitzer J, et al. Ultra-low dose - new approaches in menopausal hormone therapy. Climacteric 2015;18(2):182-6. https://doi.org/10.3109/13697137.2014.975198
  30. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-71. https://doi.org/10.1097/gme.0b013e31824b970a
  31. Marjoribanks J, Farquhar CM, Roberts H, et al. Cochrane corner: longterm hormone therapy for perimenopausal and postmenopausal women. Heart 2017 Jul 24.
  32. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause- 2017 update. Endocr Pract 2017;23(7):869-80. https://doi.org/10.4158/EP171828.PS
  33. Manassiev N, Godsland IF, Anthony J, et al. Effects of tibolone or continuous combined oestradiol/norethisterone acetate on glucose and insulin metabolism. Clinical Endocrinology 2013;78:297-302. https://doi.org/10.1111/j.1365-2265.2012.04491.x
  34. Inan I, Kelekci S, Yilmaz B. Psychological effects of tibolone and sequential estrogen-progestogen therapy in perimenopausal women. Gynecol Endocrinol 2005;20(2):64-7. https://doi.org/10.1080/09513590400020963
  35. Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016;10:CD008536.